Rheumatic diseases

Disease2 papersMeSH D012216

Humans1

Trial sponsors

NYU Langone Health
1 trialPhase 280 people

Funding

National Institute of Arthritis and Musculoskeletal and Skin DiseasesUS$171.4k1 grant since 2025

Mentoring Patient-Oriented Research Leveraging Bioinformatics to Study CV Risk in Rheumatic Disease
National Institute of Arthritis and Musculoskeletal and Skin DiseasesBrigham and Women's HospitalUS$171.4k2025–2029

Latest

6

PLOS OneResearch9 Sep

Effects of exercise on muscle strength and characteristics in rheumatic diseases and sarcopenia: Protocol for the Care for Muscle (C4M) Study

Resistance training

Zhonghua Yi Xue Za ZhiReview7 Sep

[Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy]

GLP-1 receptor agonists

Clinical TherapeuticsReview26 Aug

Exercise as a Core Component of Axial Spondyloarthritis Management: Translating Evidence into Clinical Practice

RMD OpenHumans25 Aug

Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort

GLP-1 receptor agonists

Therapeutic Advances in Musculoskeletal DiseaseReview25 Aug

Frailty in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: Current evidence and knowledge gaps

Rheumatoid arthritis

AHA Scientific Sessions 2025 AbstractHumans3 Nov

The Effects of Autoimmune Rheumatic Diseases on the Development of Clonal Hematopoiesis